Huarte, E., Peel, M. T., Verbist, K., Fay, B. L., Bassett, R., Albeituni, S., . . . Smith, P. A. (2021). Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Front Pharmacol.

Huarte, Eduardo, Michael T. Peel, Katherine Verbist, Brittany L. Fay, Rachel Bassett, Sabrin Albeituni, Kim E. Nichols, i Paul A. Smith. "Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome." Front Pharmacol 2021.

Huarte, Eduardo, et al. "Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome." Front Pharmacol 2021.